Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials (Galvano et al., J Bone Oncol 2019; 18:100252)

Detalles Bibliográficos
Autores principales: Galvano, Antonio, Scaturro, Dalila, Bazan, Viviana, Letizia Mauro, Giulia, Russo, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385536/
https://www.ncbi.nlm.nih.gov/pubmed/32742917
http://dx.doi.org/10.1016/j.jbo.2020.100295
_version_ 1783563805874192384
author Galvano, Antonio
Scaturro, Dalila
Bazan, Viviana
Letizia Mauro, Giulia
Russo, Antonio
author_facet Galvano, Antonio
Scaturro, Dalila
Bazan, Viviana
Letizia Mauro, Giulia
Russo, Antonio
author_sort Galvano, Antonio
collection PubMed
description
format Online
Article
Text
id pubmed-7385536
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-73855362020-07-30 Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials (Galvano et al., J Bone Oncol 2019; 18:100252) Galvano, Antonio Scaturro, Dalila Bazan, Viviana Letizia Mauro, Giulia Russo, Antonio J Bone Oncol Commentary Elsevier 2020-04-28 /pmc/articles/PMC7385536/ /pubmed/32742917 http://dx.doi.org/10.1016/j.jbo.2020.100295 Text en © 2020 Published by Elsevier GmbH. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Commentary
Galvano, Antonio
Scaturro, Dalila
Bazan, Viviana
Letizia Mauro, Giulia
Russo, Antonio
Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials (Galvano et al., J Bone Oncol 2019; 18:100252)
title Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials (Galvano et al., J Bone Oncol 2019; 18:100252)
title_full Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials (Galvano et al., J Bone Oncol 2019; 18:100252)
title_fullStr Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials (Galvano et al., J Bone Oncol 2019; 18:100252)
title_full_unstemmed Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials (Galvano et al., J Bone Oncol 2019; 18:100252)
title_short Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials (Galvano et al., J Bone Oncol 2019; 18:100252)
title_sort reply to: denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? a systematic review and a meta-analysis of randomized trials (galvano et al., j bone oncol 2019; 18:100252)
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385536/
https://www.ncbi.nlm.nih.gov/pubmed/32742917
http://dx.doi.org/10.1016/j.jbo.2020.100295
work_keys_str_mv AT galvanoantonio replytodenosumabforbonehealthinprostateandbreastcancerpatientsreceivingendocrinetherapyasystematicreviewandametaanalysisofrandomizedtrialsgalvanoetaljboneoncol201918100252
AT scaturrodalila replytodenosumabforbonehealthinprostateandbreastcancerpatientsreceivingendocrinetherapyasystematicreviewandametaanalysisofrandomizedtrialsgalvanoetaljboneoncol201918100252
AT bazanviviana replytodenosumabforbonehealthinprostateandbreastcancerpatientsreceivingendocrinetherapyasystematicreviewandametaanalysisofrandomizedtrialsgalvanoetaljboneoncol201918100252
AT letiziamaurogiulia replytodenosumabforbonehealthinprostateandbreastcancerpatientsreceivingendocrinetherapyasystematicreviewandametaanalysisofrandomizedtrialsgalvanoetaljboneoncol201918100252
AT russoantonio replytodenosumabforbonehealthinprostateandbreastcancerpatientsreceivingendocrinetherapyasystematicreviewandametaanalysisofrandomizedtrialsgalvanoetaljboneoncol201918100252

Ejemplares similares